Along with the many benefits of a global economy hides the ever-present risk for the world wide spread of infectious disease. While significant outbreaks of the flu in the recent past involving millions of individuals could be contained, the emergence and rapid spread of the SARS-CoV-2 virus revealed how vulnerable and unprepared the world population was to combat a previously unknown human pathogen. To limit the loss of life and economic disruption resulting from a future global event, steps toward pandemic preparedness are needed. A major component of being prepared is having the necessary tools available to act quickly to protect human health. In the ongoing pandemic, vaccines emerged as the best way to protect healthy populations and prevent hospitalization or death among those individuals who become infected. However, vaccine availability and logistical constraints regarding their distribution has left a significant proportion of the world's population still waiting for their first dose. The ability to quickly discover and develop vaccines which can be administered on a large scale is one solution towards solving this current problem. In support of this effort, it is the goal of this Phase I project to identify TLR4 agonists with immunostimulatory activity suitable for the development of safe and effective vaccine adjuvants. To achieve this goal, we will combine our years of expertise in medicinal chemistry and vaccine research and development toward completing the following specific aims: 1) Establish efficient synthesis routes for pure tri-acylated monophosphate derivatives of sucrose; 2) Identify TLR4 agonists using cell-based assays, determine their cytokine production profiles, and compare them to the full TLR4 agonist mono-phospholipid A (MPLA); and 3) Determine the immunogenic potency and safety profiles of selected sucrose based TLR4 agonists in mice and compare them against an existing subunit protein vaccines targeting West Nile Virus. We expect the product from this research to enable the development of novel adjuvants to support the preparation of new vaccines to combat current and future disease threats.
Public Health Relevance Statement: Project Narrative The ongoing COVID-19 pandemic has revealed the vulnerability of the human population to yet unknown deadly viruses and the need to be prepared to meet these threats to human health. The ability to quickly development of new vaccines is one way to counter these threats. The proposed project is designed to support this effort by the discovery of new adjuvants which are safe, effective, and easy to manufacture.
Project Terms: Goals; Hawaii; Health; Recording of previous events; History; histories; Hospitalization; Hospital Admission; Human; Modern Man; Laboratories; Mus; Mice; Mice Mammals; Murine; Phospholipids; Phosphatides; Play; Production; Research; Risk; Messenger RNA; mRNA; Role; social role; Safety; Sucrose; Saccharose; Vaccines; Virus; West Nile virus; Egypt 101 virus; WNV; aluminum sulfate; Alum Adjuvant; alum; cytokine; Left; Phase; Individual; Agonist; Immunological response; host response; immune system response; immunoresponse; Immune response; Therapeutic; Attenuated; attenuate; attenuates; tool; scaffold; scaffolding; Nature; Life; Severities; Event; Route; experience; success; thermostability; thermolability; vaccine development; develop a vaccine; develop vaccines; development of a vaccine; Protein Subunits; Toxic effect; Toxicities; novel; Positioning Attribute; Position; Property; immunogenic; preventing; prevent; TLR4 gene; Homolog of Drosophila TOLL; TLR4; Toll Homologue; toll-like receptor 4; Dose; Security; Vaccine Adjuvant; Vaccine Research; vaccine-related research; Preparation; preparations; Molecular; Adjuvant; Development; developmental; pandemic disease; pandemic; Pathway interactions; pathway; preclinical study; pre-clinical study; cost; flu outbreak; influenza outbreak; designing; design; pathogen; Population; human disease; new vaccines; next generation vaccines; novel vaccines; combat; full scale manufacturing; large scale manufacturing; mass production; large scale production; pandemic disease preparedness; pandemic planning; pandemic readiness; pandemic preparedness; discover vaccines; vaccine discovery; Innate Immune System; human pathogen; COVID19; CV-19; CV19; corona virus disease 2019; coronavirus disease 2019; coronavirus disease-19; coronavirus infectious disease-19; COVID-19; 2019 novel corona virus; 2019 novel coronavirus; COVID-19 virus; COVID19 virus; CoV-2; CoV2; SARS corona virus 2; SARS-CO-V2; SARS-COVID-2; SARS-CoV-2; SARS-CoV2; SARS-associated corona virus 2; SARS-associated coronavirus 2; SARS-coronavirus-2; SARS-related corona virus 2; SARS-related coronavirus 2; SARSCoV2; Severe Acute Respiratory Coronavirus 2; Severe Acute Respiratory Distress Syndrome CoV 2; Severe Acute Respiratory Distress Syndrome Corona Virus 2; Severe Acute Respiratory Distress Syndrome Coronavirus 2; Severe Acute Respiratory Syndrome CoV 2; Severe Acute Respiratory Syndrome-associated coronavirus 2; Severe Acute Respiratory Syndrome-related coronavirus 2; Severe acute respiratory syndrome associated corona virus 2; Severe acute respiratory syndrome coronavirus 2; Severe acute respiratory syndrome related corona virus 2; Wuhan coronavirus; coronavirus disease 2019 virus; coronavirus disease-19 virus; hCoV19; nCoV2; 2019-nCoV; 2019-nCoV vaccine; COVID19 vaccine; SARS-CoV-2 vaccine; SARS-CoV2 vaccine; SARS-coronavirus-2 vaccine; Severe Acute Respiratory Syndrome CoV 2 vaccine; Severe acute respiratory syndrome coronavirus 2 vaccine; corona virus disease 2019 vaccine; coronavirus disease 2019 vaccine; coronavirus disease-19 vaccine; nCoV vaccine; nCoV-19 vaccine; nCoV19 vaccine; vaccine against 2019-nCov; vaccine against SARS-CoV-2; vaccine against SARS-CoV2; vaccine against SARS-coronavirus-2; vaccine against Severe Acute Respiratory Syndrome CoV 2; vaccine against Severe acute respiratory syndrome coronavirus 2; vaccine for novel coronavirus; COVID-19 vaccine; COVID crisis; COVID epidemic; COVID pandemic; COVID-19 crisis; COVID-19 epidemic; COVID-19 global health crisis; COVID-19 global pandemic; COVID-19 health crisis; COVID-19 public health crisis; COVID19 crisis; COVID19 epidemic; COVID19 global health crisis; COVID19 global pandemic; COVID19 health crisis; COVID19 pandemic; COVID19 public health crisis; SARS-CoV-2 epidemic; SARS-CoV-2 global health crisis; SARS-CoV-2 global pandemic; SARS-CoV-2 pandemic; SARS-CoV2 epidemic; SARS-CoV2 pandemic; SARS-coronavirus-2 epidemic; SARS-coronavirus-2 pandemic; Severe Acute Respiratory Syndrome CoV 2 epidemic; Severe Acute Respiratory Syndrome CoV 2 pandemic; Severe acute respiratory syndrome coronavirus 2 epidemic; Severe acute respiratory syndrome coronavirus 2 pandemic; corona virus disease 2019 epidemic; corona virus disease 2019 pandemic; coronavirus disease 2019 crisis; coronavirus disease 2019 epidemic; coronavirus disease 2019 global health crisis; coronavirus disease 2019 global pandemic; coronavirus disease 2019 health crisis; coronavirus disease 2019 pandemic; coronavirus disease 2019 public health crisis; coronavirus disease crisis; coronavirus disease epidemic; coronavirus disease pandemic; coronavirus disease-19 global pandemic; coronavirus disease-19 pandemic; severe acute respiratory syndrome coronavirus 2 global health crisis; severe acute respiratory syndrome coronavirus 2 global pandemic; COVID-19 pandemic; access to vaccination; access to vaccines; vaccination access; vaccination availability; vaccine availability; vaccine access; Natural Source; new chemical entity; manufacture; immune stimulatory agent; Immunostimulatory drug; immune stimulatory drug; immune stimulatory therapeutic; immunostimulatory agents; immunostimulatory biologics; Acylation; Biological Assay; Assay; Bioassay; Biologic Assays; Biotechnology; Biotech; Cells; Cell Body; Pharmaceutical Chemistry; Medicinal Chemistry; Pharmaceutic Chemistry; Communicable Diseases; Infectious Disease Pathway; Infectious Diseases; Infectious Disorder; Cessation of life; Death; Disease; Disorder; Pharmaceutical Preparations; Drugs; Medication; Pharmaceutic Preparations; drug/agent; Economics; economic; Face; faces; facial; Future
